Highlights
- Sulforaphane (SFN), a natural isothiocyanate mainly derived from cruciferous vegetables, activates the Nrf2 pathway to mediate antioxidant, anti-inflammatory, and cytoprotective effects.
- Recent randomized controlled trials (RCTs) have demonstrated SFN’s safety and pharmacokinetic profiles in humans, with varied efficacy signals reported in neurological, metabolic, psychiatric, and cardiovascular conditions.
- Systematic reviews and meta-analyses of preclinical models affirm SFN’s renoprotective and lipid-modulating properties, encouraging further clinical investigations in chronic kidney disease and metabolic syndrome.
- Emerging evidence suggests potential clinical utility of SFN in autism spectrum disorder (ASD), depression related to cardiac intervention, non-alcoholic fatty liver disease (NAFLD), and certain cancers, although larger, well-powered trials remain necessary.
Background
Sulforaphane (SFN) is a bioactive compound found predominantly in broccoli and its sprouts, characterized by potent activation of nuclear factor erythroid 2-related factor 2 (Nrf2), which governs cellular antioxidant defense and inflammatory responses. Over the past decade, SFN’s translational interest has grown substantially, fueled by mechanistic insight and epidemiological links between cruciferous vegetable intake and reduced cancer and cardiovascular risk. The clinical context covers a broad spectrum from neurodevelopmental disorders and psychiatric diseases to metabolic and kidney diseases, all conditions associated with oxidative stress and inflammation where novel adjunctive therapies are much needed.
Key Content
Pharmacokinetics, Safety, and Formulation Advances
Recent phase 1 trials, such as the 2025 study by Lawton et al., evaluated SFX-01, an enteric-coated stabilized synthetic SFN formulation, demonstrating rapid absorption and acceptable safety in healthy male adults, with mainly mild gastrointestinal adverse events and no accumulation over short-term dosing. Another randomized trial in acute subarachnoid hemorrhage patients indicated SFX-01 is safe for delivery in severely ill patients, though with limited cerebrospinal fluid penetration and no significant clinical benefit on vasospasm or functional outcomes. Variability in bioavailability, influenced by genetic factors such as GSTT1 null genotype, was noted, emphasizing the importance of personalized pharmacokinetics in future studies.
Metabolic Disorders and Insulin Resistance
Animal studies and a small randomized controlled clinical trial (2024) revealed that SFN ameliorates insulin resistance in NAFLD models by modulating gut microbiota composition and promoting short-chain fatty acids (SCFAs) production, which activate the GPR41/43-GLP1 axis, reducing inflammation and enhancing insulin sensitivity. Clinical data corroborate increased GLP-1 levels and improved insulin resistance parameters. Additionally, meta-analyses demonstrate that SFN supplementation in rodent models reduces body weight, liver weight, total cholesterol, LDL cholesterol, and triglycerides, suggesting broad metabolic benefits potentially translatable to human metabolic syndrome.
Renal Protection and Chronic Kidney Disease
A 2023 systematic review and meta-analysis consolidating 25 preclinical studies concluded that SFN significantly improves renal function markers (creatinine clearance, plasma creatinine, urea, and proteinuria), and ameliorates histopathological kidney damage (fibrosis and glomerulosclerosis). Despite showing promise, clinical trials in CKD patients undergoing hemodialysis showed neutral effects on NRF2 expression and inflammatory markers over two months, underscoring the need for optimized dosing strategies and population-specific studies.
Cancer Prevention and Epigenetic Effects
Multiple studies support epidemiological associations between broccoli intake and reduced risk of cancer, including site-specific effects in some populations. SFN’s chemopreventive effect is attributed to Nrf2 activation and epigenetic regulation of tumor suppressor genes. Animal studies reveal paternal dietary SFN combined with green tea polyphenols can prevent estrogen receptor-negative mammary cancers via epigenetic modifications across generations. Additionally, a 2022 randomized trial detected increased sulforaphane accumulation in human prostate tissue post-supplementation, providing mechanistic plausibility for its protective role against prostate cancer.
Neurodevelopmental and Psychiatric Disorders
SFN’s antioxidant and anti-inflammatory properties have been explored in autism spectrum disorder (ASD) and depression. Larger RCTs in children with ASD demonstrated mixed results, with clinician-rated scales showing some improvement but caregiver assessments and primary clinical outcomes mostly not reaching significance. Biomarker changes in glutathione metabolism and inflammation correlate with clinical features. For depression, especially post-cardiac interventions, a placebo-controlled trial showed that SFN improved depressive symptoms with favorable safety. In schizophrenia, preliminary adjunctive trials suggest potential cognitive benefits, but data remain limited.
Other Clinical Applications
Sulforaphane supplementation improved blood pressure and endothelial function in women with pregnancy-related hypertension, indicating possible therapeutic value in preeclampsia. In allergic rhinitis, broccoli sprout extract combined with corticosteroids improved nasal airflow and symptoms, highlighting a role for SFN as an antioxidant adjuvant in allergic diseases. Chronic intake attenuated exercise-induced muscle damage and inflammation, suggesting benefits in sports medicine and recovery.
Expert Commentary
The collective evidence underscores SFN as a versatile bioactive compound with multi-organ protective effects principally mediated through activation of the Nrf2 pathway and modulation of inflammation and oxidative stress. Clinical translation is challenged by variable bioavailability, differences in formulations, and heterogeneous patient populations. While preclinical models uniformly demonstrate benefits, clinical trials often yield modest efficacy signals with inconsistent results, particularly in neurodevelopmental disorders where placebo effects and assessment variability complicate interpretation. The safety profile of SFN is consistently favorable, supporting continued clinical investment.
The heterogeneity in clinical outcomes likely reflects differences in dosage, treatment duration, disease severity, and SFN formulations. The recent development of stabilized SFX-01 has improved dosing reliability but requires further large-scale, long-term trials to establish clinical efficacy across disease domains. Additionally, emerging insights into gut microbiome interactions offer promising avenues to enhance SFN’s metabolic effects.
Notably, SFN’s epigenetic modulation presents novel prevention opportunities in oncology, including transgenerational benefits as seen in animal models. The role of sulforaphane as an adjunct rather than monotherapy seems prudent, given it may enhance responses to existing treatments or ameliorate associated symptoms in complex disorders.
Conclusion
Over the past decade, sulforaphane has emerged as a promising therapeutic natural product with a broad range of biological activities relevant to human disease. Evidence from pharmacokinetic studies, preclinical models, and early-phase clinical trials highlights its potential in metabolic diseases, kidney protection, cancer chemoprevention, neurodevelopmental and psychiatric disorders, and cardiovascular health.
Future research priorities include large, well-powered, randomized controlled trials that address optimal dosing, formulation, and patient selection criteria. Further exploration into SFN’s mechanistic pathways, especially its interplay with the gut microbiome and epigenetic regulation, may unlock new preventive and therapeutic roles.
In summary, sulforaphane represents a novel, safe, and biologically plausible candidate for adjunctive therapy across a spectrum of chronic diseases characterized by oxidative stress and inflammation, warranting sustained investigative efforts.
References
- Lawton KA et al. A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants. Adv Ther. 2025;42(1):216-232. doi:10.1007/s12325-024-03018-1.
- Magalhães Z et al. A Randomised Controlled Trial of SFX-01 After Subarachnoid Haemorrhage – The SAS Study. Transl Stroke Res. 2025;16(4):1031-1043. doi:10.1007/s12975-024-01278-1.
- Yang X et al. Improving insulin resistance by sulforaphane activating the SCFAs-GPR-GLP1 signal axis. Food Funct. 2024;15(17):8644-8660. doi:10.1039/d4fo01059k.
- de Oliveira Silva K et al. Sulforaphane upregulates the mRNA expression of NRF2 and NQO1 in non-dialysis patients with chronic kidney disease. Free Radic Biol Med. 2024;221:181-187. doi:10.1016/j.freeradbiomed.2024.05.034.
- Magalhães Z et al. Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study. Nutrients. 2023;15(3):718. doi:10.3390/nu15030718.
- Panfili G et al. Sulforaphane exhibits potent renoprotective effects in preclinical models of kidney diseases: A systematic review and meta-analysis. Life Sci. 2023;322:121664. doi:10.1016/j.lfs.2023.121664.
- Harshman SW et al. Broccoli Consumption and Risk of Cancer: An Updated Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2024;16(11):1583. doi:10.3390/nu16111583.
- Pan Y et al. Accumulation of Sulforaphane and Alliin in Human Prostate Tissue. Nutrients. 2022;14(16):3263. doi:10.3390/nu14163263.
- Grgic J et al. Sulforaphane ameliorates lipid profile in rodents: an updated systematic review and meta-analysis. Sci Rep. 2021;11(1):7804. doi:10.1038/s41598-021-87367-9.
- Sahebkar A et al. Efficacy and safety of sulforaphane for treatment of mild to moderate depression in patients with history of cardiac interventions: A randomized, double-blind, placebo-controlled clinical trial. Psychiatry Clin Neurosci. 2021;75(8):250-255. doi:10.1111/pcn.13276.